Company intelligence / Profile preview
Viracta Therapeutics, Inc.
Cardiff, California, United Statesviracta.com ↗
- Ownership
- Public · VIRX
- Development stage
- Phase 2
01
Overview
In their Phase 2 NAVAL-1 trial for EBV+ PTCL, they reported overall and complete response rates of 33% and 19% respectively, with higher rates (60% ORR, 30% CRR) in second-line patients[9]. The company terminated operations in February 2025[7].
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (HDAC inhibitor)Antiviral agents
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Viracta Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viracta Therapeutics, Inc..